Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Comparative Analysis of two Methods of Measuring Antiretroviral Therapy Adherence in HIV-Infected Omani Patients.

Gaifer Z, Boulassel MR.

J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219867316. doi: 10.1177/2325958219867316.

PMID:
31389287
2.

Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma.

Boulassel MR, Al Qarni Z, Burney I, Khan H, Al-Zubaidi A, Al Naamani A, Al-Hinai H, Al-Badi A, Qureshi RN, Panjwani V, Al Farsi K.

Mol Clin Oncol. 2018 Dec;9(6):677-682. doi: 10.3892/mco.2018.1732. Epub 2018 Oct 2.

3.

Hemoglobin F as a predictor of health-related quality of life in children with sickle cell anemia.

Boulassel MR, Al-Badi A, Elshinawy M, Al-Hinai J, Al-Saadoon M, Al-Qarni Z, Khan H, Qureshi RN, Wali Y.

Qual Life Res. 2019 Feb;28(2):473-479. doi: 10.1007/s11136-018-2031-0. Epub 2018 Oct 22.

PMID:
30350256
4.

Does sickle cell disease have a psychosomatic component? A particular focus on anxiety and depression.

Toumi ML, Merzoug S, Boulassel MR.

Life Sci. 2018 Oct 1;210:96-105. doi: 10.1016/j.lfs.2018.08.066. Epub 2018 Aug 29. Review.

PMID:
30171881
5.

Stability of fetal hemoglobin levels in patients receiving metformin therapy.

Boulassel MR, El-Hussain AI, Hassan MM, Toumi ML, Merzoug S, Al-Qarni Z, Khan H, Gaifer Z, Al-Farsi K, Al-Khabori M, Al Huneini M, Al-Kindi S.

Haematologica. 2018 Oct;103(10):e440-e442. doi: 10.3324/haematol.2018.190967. Epub 2018 Apr 26. No abstract available.

6.

Regulatory B Cells Are Functionally Impaired in Patients Having Hemophilia A With Inhibitors.

Boulassel MR, Al-Ghonimi M, Al-Balushi B, Al-Naamani A, Al-Qarni Z, Wali Y, Elshinawy M, Al-Shezawi M, Khan H, Nazir H, Khater D, Pathare A, Al-Kindi S.

Clin Appl Thromb Hemost. 2018 May;24(4):618-624. doi: 10.1177/1076029617702244. Epub 2017 Apr 10.

7.

Leishmania Infantum and Epstein-Barr Virus Co-Infection in a Patient with Hemophagocytosis.

Gaifer Z, Boulassel MR.

Infect Dis Rep. 2016 Dec 31;8(4):6545. doi: 10.4081/idr.2016.6545. eCollection 2016 Dec 31.

8.

Accuracy of Platelet Counting by Optical and Impedance Methods in Patients with Thrombocytopaenia and Microcytosis.

Boulassel MR, Al-Farsi R, Al-Hashmi S, Al-Riyami H, Khan H, Al-Kindi S.

Sultan Qaboos Univ Med J. 2015 Nov;15(4):e463-8. doi: 10.18295/squmj.2015.15.04.004. Epub 2015 Nov 23.

9.

Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.

Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, Croughs T, Beq S, Lafaye de Micheaux S, Yao MD, Ober A, Wilson EM, Natarajan V, Imamichi H, Boulassel MR, Lederman MM, Routy JP.

PLoS Pathog. 2014 Jan 30;10(1):e1003890. doi: 10.1371/journal.ppat.1003890. eCollection 2014 Jan.

10.

Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection.

Breton G, Chomont N, Takata H, Fromentin R, Ahlers J, Filali-Mouhim A, Riou C, Boulassel MR, Routy JP, Yassine-Diab B, Sékaly RP.

J Immunol. 2013 Sep 1;191(5):2194-204. doi: 10.4049/jimmunol.1200646. Epub 2013 Aug 5.

11.

HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.

Pezeshki AM, Azar GA, Mourad W, Routy JP, Boulassel MR, Denzin LK, Thibodeau J.

Hum Immunol. 2013 Oct;74(10):1280-7. doi: 10.1016/j.humimm.2013.05.010. Epub 2013 Jun 10.

PMID:
23756162
12.

Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.

Routy B, Boulassel MR, Spurll GM, Warner MN, Routy JP.

Am J Ther. 2013 Mar-Apr;20(2):219-22. doi: 10.1097/MJT.0b013e318258905e.

PMID:
23466621
13.
14.

Autologous HIV-1 clade-B Nef peptides elicit increased frequency, breadth and function of CD8+ T-cells compared to consensus peptides.

Doroudchi M, Yegorov O, Baumgartner T, Kernaleguen AE, Breton G, Ndongala ML, Boulassel MR, Routy JP, Bernard NF, Sékaly RP, Yassine-Diab B.

PLoS One. 2012;7(11):e49562. doi: 10.1371/journal.pone.0049562. Epub 2012 Nov 19.

15.

Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection.

Trautmann L, Mbitikon-Kobo FM, Goulet JP, Peretz Y, Shi Y, Van Grevenynghe J, Procopio FA, Boulassel MR, Routy JP, Chomont N, Haddad EK, Sekaly RP.

Blood. 2012 Oct 25;120(17):3466-77. doi: 10.1182/blood-2012-04-422550. Epub 2012 Sep 6.

16.

CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.

Peretz Y, He Z, Shi Y, Yassine-Diab B, Goulet JP, Bordi R, Filali-Mouhim A, Loubert JB, El-Far M, Dupuy FP, Boulassel MR, Tremblay C, Routy JP, Bernard N, Balderas R, Haddad EK, Sékaly RP.

PLoS Pathog. 2012;8(8):e1002840. doi: 10.1371/journal.ppat.1002840. Epub 2012 Aug 16.

17.

A new cellular weapon to kill leukaemic B-cells.

Boulassel MR.

Sultan Qaboos Univ Med J. 2012 May;12(2):137-9. Epub 2012 Apr 9. No abstract available.

18.

Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy.

Routy JP, Boulassel MR, Nicolette CA, Jacobson JM.

J Med Virol. 2012 Jun;84(6):885-9. doi: 10.1002/jmv.23297.

PMID:
22499010
19.

The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid.

Wacleche VS, Chomont N, Gosselin A, Monteiro P, Goupil M, Kared H, Tremblay C, Bernard N, Boulassel MR, Routy JP, Ancuta P.

PLoS One. 2012;7(3):e32964. doi: 10.1371/journal.pone.0032964. Epub 2012 Mar 28.

20.

Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.

Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR.

HIV Med. 2012 May;13(5):291-6. doi: 10.1111/j.1468-1293.2011.00975.x. Epub 2012 Jan 26.

21.

The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.

Sheehan NL, van Heeswijk RP, Foster BC, Akhtar H, Singhal N, Seguin I, DelBalso L, Bourbeau M, Chauhan BM, Boulassel MR, Burger DM, Lalonde RG, Cameron DW.

Molecules. 2012 Jan 12;17(1):688-702. doi: 10.3390/molecules17010688.

22.

Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation.

Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE, Ambrozak DR, Scheinberg P, Boulassel MR, Routy JP, Koup RA, Douek DC, Sekaly RP, Trautmann L.

J Immunol. 2012 Feb 1;188(3):1156-67. doi: 10.4049/jimmunol.1102610. Epub 2011 Dec 30.

23.

CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.

Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP.

J Clin Virol. 2012 Jan;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018. Epub 2011 Oct 22.

PMID:
22019250
24.

Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis.

van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y, Filali-Mouhim A, Dupuy FP, Procopio FA, Chomont N, Balderas RS, Said EA, Boulassel MR, Tremblay CL, Routy JP, Sékaly RP, Haddad EK.

J Clin Invest. 2011 Oct;121(10):3877-88. doi: 10.1172/JCI59211. Epub 2011 Sep 19. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2704.

25.

T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers.

Kamya P, Tsoukas CM, Boulet S, Routy JP, Thomas R, Côté P, Boulassel MR, Lessard B, Kaul R, Ostrowski M, Kovacs C, Tremblay CL, Bernard NF.

AIDS Res Ther. 2011 Jun 16;8(1):20. doi: 10.1186/1742-6405-8-20.

26.

Relative contribution of HIV-specific functional lymphocyte subsets restricted by protective and non-protective HLA alleles.

Peretz Y, Marra O, Thomas R, Legault D, Côté P, Boulassel MR, Rouleau D, Routy JP, Sékaly RP, Tsoukas CM, Tremblay C, Bernard NF.

Viral Immunol. 2011 Jun;24(3):189-98. doi: 10.1089/vim.2010.0117.

PMID:
21668360
27.

Forced expression of HLA-DM at the surface of dendritic cells increases loading of synthetic peptides on MHC class II molecules and modulates T cell responses.

Pezeshki AM, Côté MH, Azar GA, Routy JP, Boulassel MR, Thibodeau J.

J Immunol. 2011 Jul 1;187(1):74-81. doi: 10.4049/jimmunol.1002747. Epub 2011 May 27.

28.

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors.

J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6.

29.

Effect of antiretroviral therapy on HIV-1 genetic evolution during acute infection.

Chamberland A, Sylla M, Boulassel MR, Baril JG, Côté P, Thomas R, Trottier B, Rouleau D, Routy JP, Tremblay C; Investigators of the Primary HIV-Infection Cohort of Montreal.

Int J STD AIDS. 2011 Mar;22(3):146-50. doi: 10.1258/ijsa.2010.010292.

PMID:
21464451
30.

Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7.

Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said EA, Kared H, Grandvaux N, Boulassel MR, Routy JP, Ancuta P.

J Immunol. 2011 Apr 15;186(8):4618-30. doi: 10.4049/jimmunol.1004151. Epub 2011 Mar 11.

31.

A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease.

Bouchentouf M, Forner K, Cuerquis J, Boulassel MR, Routy JP, Waller EK, Quyyumi AA, Paradis P, Schiffrin EL, Galipeau J.

Cell Transplant. 2011;20(9):1431-43. doi: 10.3727/096368910X557164. Epub 2011 Feb 3.

PMID:
21294961
32.

Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes.

Hanafi LA, Bolduc M, Gagné ME, Dufour F, Langelier Y, Boulassel MR, Routy JP, Leclerc D, Lapointe R.

Vaccine. 2010 Aug 2;28(34):5617-26. doi: 10.1016/j.vaccine.2010.06.024. Epub 2010 Jun 25.

PMID:
20600515
33.

Changes in function of HIV-specific T-cell responses with increasing time from infection.

Ndongala ML, Kamya P, Boulet S, Peretz Y, Rouleau D, Tremblay C, Leblanc R, Côté P, Baril JG, Thomas R, Vézina S, Boulassel MR, Routy JP, Sékaly RP, Bernard NF.

Viral Immunol. 2010 Apr;23(2):159-68. doi: 10.1089/vim.2009.0084.

34.

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.

Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP.

Nat Med. 2010 Apr;16(4):452-9. doi: 10.1038/nm.2106. Epub 2010 Mar 7.

35.

IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication.

Iannello A, Boulassel MR, Samarani S, Tremblay C, Toma E, Routy JP, Ahmad A.

J Leukoc Biol. 2010 May;87(5):857-67. doi: 10.1189/jlb.1009701. Epub 2010 Jan 26.

PMID:
20103765
36.

HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication.

Iannello A, Boulassel MR, Samarani S, Tremblay C, Toma E, Routy JP, Ahmad A.

J Infect Dis. 2010 Feb 15;201(4):608-17. doi: 10.1086/650314.

PMID:
20078197
37.

Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection.

Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, Wacleche V, El-Far M, Boulassel MR, Routy JP, Sekaly RP, Ancuta P.

J Immunol. 2010 Feb 1;184(3):1604-16. doi: 10.4049/jimmunol.0903058. Epub 2009 Dec 30.

38.

Monocyte derivatives promote angiogenesis and myocyte survival in a model of myocardial infarction.

Bouchentouf M, Paradis P, Forner KA, Cuerquis J, Boivin MN, Zheng J, Boulassel MR, Routy JP, Schiffrin EL, Galipeau J.

Cell Transplant. 2010;19(4):369-86. doi: 10.3727/096368909X484266. Epub 2009 Dec 18.

PMID:
20021736
39.

Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions.

Iannello A, Samarani S, Debbeche O, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A.

Curr HIV Res. 2010 Mar;8(2):147-64. Review.

PMID:
19954415
40.

Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study.

Iannello A, Boulassel MR, Samarani S, Debbeche O, Tremblay C, Toma E, Routy JP, Ahmad A.

J Immunol. 2010 Jan 1;184(1):114-26. doi: 10.4049/jimmunol.0901967. Epub 2009 Nov 30.

41.

Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance.

Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, Routy JP, Boulassel MR, Krzemien U, Tanguay S, Lattouf JB, Arbour N, Lapointe R.

J Immunol. 2009 Dec 15;183(12):7752-60. doi: 10.4049/jimmunol.0901004.

42.

The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation.

Penafuerte C, Bautista-Lopez N, Boulassel MR, Routy JP, Galipeau J.

Cancer Res. 2009 Dec 1;69(23):9020-8. doi: 10.1158/0008-5472.CAN-09-2322. Epub 2009 Nov 17. Erratum in: Cancer Res. 2010 Jul 15;70(14):6106. Mohamed-Rachid, Boulassel [corrected to Boulassel, Mohamed-Rachid].

43.

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.

Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L, Sékaly RP.

Clin Immunol. 2010 Feb;134(2):140-7. doi: 10.1016/j.clim.2009.09.009. Epub 2009 Nov 4.

44.

Role of interleukin-18 in the development and pathogenesis of AIDS.

Iannello A, Samarani S, Debbeche O, Tremblay C, Toma E, Boulassel MR, Routy JP, Ahmad A.

AIDS Rev. 2009 Jul-Sep;11(3):115-25. Review.

PMID:
19654853
45.

siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.

Breton G, Yassine-Diab B, Cohn L, Boulassel MR, Routy JP, Sékaly RP, Steinman RM.

J Clin Immunol. 2009 Sep;29(5):637-45. doi: 10.1007/s10875-009-9313-9. Epub 2009 Jun 27.

46.

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP.

Nat Med. 2009 Aug;15(8):893-900. doi: 10.1038/nm.1972. Epub 2009 Jun 21.

47.

The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.

Tcherepanova I, Starr A, Lackford B, Adams MD, Routy JP, Boulassel MR, Calderhead D, Healey D, Nicolette C.

PLoS One. 2009 Jun 10;4(6):e5853. doi: 10.1371/journal.pone.0005853.

48.

Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells.

Iannello A, Samarani S, Debbeche O, Ahmad R, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A.

J Virol. 2009 Jun;83(12):5999-6010. doi: 10.1128/JVI.02350-08. Epub 2009 Apr 1.

49.

HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load.

Ndongala ML, Peretz Y, Boulet S, Doroudchi M, Yassine-Diab B, Boulassel MR, Rouleau D, Tremblay C, LeBlanc R, Routy JP, Sékaly RP, Bernard NF.

Clin Immunol. 2009 May;131(2):277-87. doi: 10.1016/j.clim.2008.11.006. Epub 2009 Jan 8.

PMID:
19135418
50.

Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts.

Iannello A, Tremblay C, Routy JP, Boulassel MR, Toma E, Ahmad A.

Viral Immunol. 2008 Sep;21(3):385-8. doi: 10.1089/vim.2008.0025.

PMID:
18788946

Supplemental Content

Loading ...
Support Center